Publication Topic

Racz L, Gauthier A, Bare J, Heintz M, Feifarek D, Kennedy S, Panko J. 2024. Assessment of perfluorocarboxylic acids in fluorinated high-density polyethylene containers and estimation of potential non-cancer risks associated with anticipated use scenarios. Regul Toxicol Pharmacol 147(Feb):105560; doi: 10.1016/j.yrtph.2024.105560. PMID: 38182014.

Jacobellis M, Bain L, Baldwin W. Disruption of energy homeostasis by PFAS mixtures. Southeastern Society of Toxicology, University of Georgia, Athens, GA, 2023.

Rogers JM, Heintz MM, Thompson CM, Haws LC. 2023. A putative adverse outcome network for neonatal mortality and lower birth weight in rodents: Applicability to per- and polyfluoroalkyl substances and relevance to human health. Birth Defects Res 115(11)1011-1062; doi: 10.1002/bdr2.2185. PMID: 37219003.

Thompson CM, Heintz MM, Wolf JC, Cheru R, Haws LC, Cullen JM. 2023. Assessment of mouse liver histopathology following exposure to HFPO-DA with emphasis on understanding mechanisms of hepatocellular death. Toxicol Pathol 51(1–2):4–14; doi: 10.1177/01926233231159078. PMID: 36987989.

Heintz MM, Haws LC, Klaunig JE, Cullen JM, Thompson CM. 2023. Assessment of the mode of action underlying development of liver lesions in mice following oral exposure to HFPO-DA and relevance to humans. Toxicol Sci 192(1):15–29; doi: 10.1093/toxic/kfad004. PMID: 36629480.

Richard AM, Lougee R, Adams M, Hidle H, Yang C, Rathman J, Magdziarz T, Bienfait B, Williams AJ, Patlewicz G. 2023. A new CSRML structure-based fingerprint method for profiling and categorizing per- and polyfluoroalkyl substances (PFAS). Chem Res Toxicol 36(3):508–534; doi: 10.1021/acs.chemrestox.2c00403. PMID: 36862450.

Carstens KE, Freudenrich T, Wallace K, Choo S, Carpenter A, Smeltz M, Clifton MS,…, Patlewicz G, et al. 2023. Evaluation of per- and polyfluoroalkyl substances (PFAS) in vitro toxicity testing for developmental neurotoxicity. Chem Res Toxicol 36(3):402–419; doi: 10.1021/acs.chemrestox.2c00344. PMID: 36821828.

Houck K, Paul Friedman K, Feshuk M, Patlewicz G, Smeltz M, Clifton S, Wetmore BA, Velichko S, et al. 2023. Evaluation of 147 perfluoroalkyl substances for immunotoxic and other (patho)physiological activities through phenotypic screening of human primary cells. ALTEX 40(2):248–270; doi: 10.14573/altex.220304. PMID: 36129398.

East A, Dawson DE, Brady S, Vallero DA, Tornero-Velez R. 2023. A scoping assessment of implemented toxicokinetic models of per- and polyfluoro-alkyl substances, with a focus on one-compartment models. Toxics 11(2):163; doi: 10.3390/toxics11020163. PMID: 36851038.

Patlewicz G, Richard AM, Williams AJ, Judson RS, Thomas RS. 2022. Towards reproducible structure-based chemical categories for PFAS to inform and evaluate toxicity and toxicokinetic testing. Comput Toxicol 24(Nov):100250; doi: 10.1016/j.comtox.2022.100250. PMID: 36969381.

Heintz MM, Chappell GA, Thompson CM, Haws LC. 2022. Evaluation of transcriptomic responses in livers of mice exposed to the short-chain PFAS compound HFPO-DA. Front Toxicol 4(Jun 27):937168; doi: 10.3389/ftox.2022.937168. PMID: 35832492.

Patlewicz G, Richard A, Williams A, Judson R, Thomas R. Towards reproducible structure-based chemical categories for PFAS to inform and evaluate toxicity and toxicokinetic testing. American Society for Cellular and Computation Toxicology 11^th Annual Meeting, Chapel Hill, NC, October 2022.

Carstens K, Carpenter A, FreudenrichT, Wallace K, Choo S, Patlewicz G, et al. Evaluation of per- and poly fluoroalkyl substances (PFAS) in vitro toxicity testing for developmental neurotoxicity. American Society for Cellular and Computation Toxicology 11^th Annual Meeting, Chapel Hill, NC, October 2022.

Lea IA, Pham LL, Antonijevic T, Thompson C, Borghoff SJ. 2022. Assessment of the applicability of the threshold of toxicological concern for per- and polyfluoroalkyl substances. Regul Toxicol Pharmacol 133(August):105190; doi: 10.1016/j.yrtph.2022.105190. PMID: 35662637.

Carlson LM, Angrish M, Shirke AV, Radke EG, Schulz B, Kraft A, Judson RS, Patlewicz G, et al. 2022. Systematic evidence map for over one hundred and fifty per- and polyfluoroalkyl substances (PFAS). Environ Health Perspect 130(5):56001; doi: 10.1289/EHP10343. PMID: 35580034.

Racz L. PFAS: How did we get here and where are we going? Keynote address at Alliance of Hazardous Materials Professionals national meeting, Las Vegas, NV, March 2022.

Williams AJ, Gaines LG, Grulke CM, Lowe CN, Sinclair G, Samano V, Thillainadarajah I, Meyer B, Patlewicz G, Richard AM. 2022. Assembly and curation of list of per- and polyfluoroalkyl substances (PFAS) to support environmental science research. Front Environ Sci 10(Apr 5):1-13; doi: 10.3389/fenvs.2022.850019. PMID: 35936994.

Hearon SE, Orr AA, Moyer H, Wang M, Tamamis P, Phillips TD. 2022. Montmorillonite clay-based sorbents decrease the bioavailability of per- and polyfluoralkyl substances (PFAS) from soil and their translocation to plants. Environ Res 205(Apr 1):112433; doi: 10.1016/j.envres.2021.112433. PMID: 34875259.

Rogers JM, Heintz MM, Thompson CM, Haws LC. Development of a putative adverse outcome pathway for neonatal mortality in rodents: Implications for human health risk assessments of PFAS. Poster presented at Society of Toxicology 61st Annual Meeting, San Diego, CA, March 2022.

Richard AM, Hidle H, Patlewicz G, Williams AJ. 2022. Identification of branched and linear forms of PFOA and potential precursors: A user-friendly SMILES structure-based approach. Front Environ Sci 10(Mar 24):865488; doi: 10.3389/fenvs.2022.865488. PMID: 35494535.